HC006 + pembrolizumab

**HC006 + pembrolizumab** is a combination therapy comprising HC006 and pembrolizumab. Pembrolizumab is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor on T cells, functioning as a checkpoint inhibitor to enhance anti-tumor immune responses. HC006 is a code name for an investigational compound; publicly available information does not provide a precise molecular identity or detailed mechanism for HC006. This combination is under investigation for antitumor effects, where pembrolizumab's immune checkpoint blockade would be complemented by the immunomodulatory or antineoplastic activity of HC006. Clinical studies are evaluating the effectiveness, safety, and immune response profile of this combination.